Ask about this productRelated genes to: ZNF703 antibody
- Gene:
- ZNF703 NIH gene
- Name:
- zinc finger protein 703
- Previous symbol:
- -
- Synonyms:
- FLJ14299, ZNF503L, NLZ1, Zpo1, ZEPPO1
- Chromosome:
- 8p11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2005-08-16
- Date modifiied:
- 2016-11-01
Related products to: ZNF703 antibody
Related articles to: ZNF703 antibody
- Alendronate effectively inhibits osteoclastic bone resorption and is considered as first line treatment of osteoporosis. Additionally, several studies suggest a beneficial effect on mortality that goes beyond life-extending effects attributed to the well-established fracture risk reduction. However, mechanisms of the mortality reducing effect of bisphosphonates are unclear. The turquoise killifish Nothobranchius furzeri (N. furzeri), a well-known model of accelerated aging, exhibits an extremely short life cycle and thus could represent a suitable model for survival studies. The aim of this study was to test the effect of alendronate on the life span and bone properties of N. furzeri. At the age of 16 weeks 89 female fish were divided into a treatment (10 μM alendronate, n = 44) and a control (n = 45) group and monitored for survival. Vertebral bodies of deceased fish were examined by micro-CT and bone histomorphometry. RNA sequencing and gene expression analysis was done from isolated tissues of heart, spleen, liver, muscle and kidney. The alendronate group showed a higher survival (+7%; p = 0.0070). Micro-CT evaluation showed higher values for bone (+2%; p = 0.0013) and tissue mineral density (+3%; p = 0.0159) in the control group. Bone histomorphometry displayed higher values for number of osteoblasts/bone perimeter (p = 0.0340) in the alendronate group. RNA sequencing revealed differences in gene expression and biological function under alendronate treatment. Furthermore, we determined a reduced ZNF703 expression in the alendronate group. Our results indicate that alendronate has a positive effect on survival of N. furzeri and alters bone mineralization. Moreover, it effects several non-bone related pathways and leads to strong organ-specific effects. - Source: PubMed
Publication date: 2026/04/18
Butylina MariaKothmayer MichaelBasílio JoséWahl-Figlash KatharinaGelles KatharinaFrommlet FlorianPusch OliverPietschmann Peter - To evaluate changes in gene expression activity during preoperative testing for tumor hormone sensitivity to aromatase inhibitors and tamoxifen in postmenopausal women with ESR+/HER2- breast cancer. - Source: PubMed
Kometova V VBurmenskaya O VTrofimov D YuRodionova M VRodionov V VAshrafyan L AMikhaleva L M - ZNF703, a member of the NET/NLZ family, plays a critical role in individual development and cancer progression. Despite its significance, a comprehensive pan-cancer analysis of ZNF703 remains underexplored. In this study, we performed a systematic pan-cancer analysis to elucidate the mechanistic and functional roles of ZNF703 in tumorigenesis. Our findings reveal that elevated ZNF703 expression is significantly correlated with cancer progression, adverse clinical outcomes, and the enrichment of immune cells within the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), CD8 T cells, and M2 macrophages, suggesting its pivotal role in modulating tumor immunity. Mechanistically, ZNF703 regulates tumor immunity by binding to promoter sequences, thereby suppressing the expression of CD274, ICAM1, and CXCL3, which may facilitate tumor immune escape. Additionally, we identified functional hub genes associated with ZNF703, including DDHD2, LSM1, and BAG4. Notably, ZNF703, DDHD2, LSM1, and BAG4 are co-localized within the amplicons at the chromosome 8p11-p12 region, indicating a potential cooperative role in driving cancer initiation and progression. Collectively, these findings underscore the essential roles of ZNF703 in cancer development, patient prognosis, and the regulation of anti-tumor immunity, highlighting its potential as a biomarker for cancer detection and as a novel immunotherapeutic target. - Source: PubMed
Publication date: 2025/09/29
Shi XianliLie JingyuLi RuiChen HaomingZhang Rongxin - As a clinically heterogeneous breast cancer subtype, triple-negative breast cancer (TNBC) currently lacks effective targeted therapies. The subtype-specific heterogeneity of tumor phenotypes and gene expression programs poses challenges for the treatment of TNBC. However, while progress has been made in understanding the epigenetic and molecular mechanisms of TNBC, studies on the role of super-enhancers (SEs) in TNBC remain limited, particularly in the exploration of preclinical models at the subtype level. This study constructed a transcriptome-driven subtype classifier for cell lines, characterized epigenetic heterogeneity in the Fudan University Shanghai Cancer Center (FUSCC) TNBC subtypes, and mapped subtype-specific super-enhancers landscape. We revealed SE-mediated regulatory mechanisms underlying subtype divergence and proposed epigenetically informed therapeutic targets. We identified ZNF703 as a regulator in the LAR subtype and NesBCL11A in the BLIS subtype, both with clinical implications. This research offers new insights into TNBC's molecular mechanisms and potential targets for subtype-specific therapies. - Source: PubMed
Publication date: 2025/08/13
Lu ZhilinWang ZhenchangZhu WenyongCai ShuyangSun XiaoHuang Hao - Precision oncology is making remarkable advancements in optimizing patient care by personalizing treatments. To date, the US Food and Drug Administration (FDA) has approved poly(ADP-ribose) polymerase inhibitors (PARPi) olaparib (Lynparza, AstraZeneca and Merck) and talazoparib (Talzenna, Pfizer Oncology Together™) for germline or somatic BRCA1/2-mutated metastatic breast cancer (BC) patients, and PI3K inhibitor alpelisib (Piqray, Novartis) plus fulvestrant for patients with hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+HER2-) PIK3CA-mutated advanced BC. In addition, the FDA approved capivasertib (Trucap, AstraZeneca) for HR+HER2- locally advanced or metastatic BC patients with one or more AKT1, PIK3CA, or PTEN alterations. Finally, the FDA recently approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal patients with ER+ HER2- ESR1-mutated advanced or metastatic BC with disease progression following at least one line of endocrine therapy. - Source: PubMed
Publication date: 2025/04/07
Kang IreneNaghi LeahYost Susan EMortimer Joanne